US 7,531,174 B2
	Cripto blocking antibodies and uses thereof
Michele Sanicola-Nadel, Winchester, Mass. (US); Kevin P. Williams, Chapel Hill, N.C. (US); Susan Gail Schiffer, Lexington, Mass. (US); and Paul Rayhorn, Foxborough, Mass. (US)
Assigned to Biogen Idec MA Inc., Cambridge, Mass. (US)
Filed on Oct. 23, 2003, as Appl. No. 10/693,538.
Application 10/693538 is a continuation of application No. PCT/US02/11950, filed on Apr. 17, 2002.
Claims priority of provisional application 60/367002, filed on Mar. 22, 2002.
Claims priority of provisional application 60/301091, filed on Jun. 26, 2001.
Claims priority of provisional application 60/293020, filed on May 17, 2001.
Claims priority of provisional application 60/286782, filed on Apr. 26, 2001.
Prior Publication US 2004/0146940 A1, Jul. 29, 2004
Int. Cl. A61K 39/395 (2006.01); A61K 38/00 (2006.01)

U.S. Cl. 424—141.1  [424/130.1; 424/178.1; 424/277.1; 530/387.1]

228 Claims

1. A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto comprised in the domain spanning amino acid residues from amino acid 46 to amino acid 62 of SEQ ID NO:1 or amino acid residues from about amino acid 46 to about amino acid 62 of SEQ ID NO:2 in an effective amount.